Skip to main content
    T

    Tvardi Therapeutics, Inc. (TVRD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.08 (-6.78%)

    Market Cap: $15.74M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Tvardi Therapeutics, Inc. (TVRD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Tvardi Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$18.21M, operating cash flow was -$23.50M and free cash flow was -$23.50M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$6.12M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $26.75M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$20.97M-49.9%70.6%-579.4%-565.2%
    Dec 2022$41.87M+81.8%82.6%-209.1%-204.2%
    Dec 2021$23.03M-83.0%100.0%-386.8%-384.1%
    Dec 2020$135.08M+579.3%100.0%4.0%6.2%
    Dec 2019$19.89M+47.6%100.0%-561.6%-534.9%
    Dec 2018$13.47M+1378.5%100.0%-574.5%-549.5%
    Dec 2017$911.00K+959.3%100.0%-6529.6%-6380.4%
    Dec 2016$86.00KN/A100.0%-67907.0%-66604.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$20.97M$41.87M$23.03M$135.08M$19.89M$13.47M$911.00K$86.00K
    Cost of revenue$0$0$6.17M$7.27M$0$0$0$0$0$0
    Gross profit$0$0$14.79M$34.60M$23.03M$135.08M$19.89M$13.47M$911.00K$86.00K
    Research and development$18.01M$23.65M$108.51M$91.88M$82.70M$107.85M$113.82M$75.53M$48.52M$49.25M
    Operating income-$26.75M-$28.11M-$121.50M-$87.53M-$89.08M$5.38M-$111.68M-$77.38M-$59.48M-$58.40M
    Net income-$18.21M-$29.40M-$118.51M-$85.47M-$88.44M$8.41M-$106.37M-$74.01M-$58.13M-$57.28M
    EBITDAN/A-$28.01M-$118.05M-$84.96M-$86.67M$8.89M-$107.77M-$75.85M-$57.25M-$56.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0-$2.57M$0$0$0-$2.13M$0$0$2.13M$3.00M
    Gross profit$0$0$0-$2.57M$0$0$0-$1.51M$0$0$1.51M$2.40M
    Operating income-$6.33M-$6.63M-$7.05M-$9.55M-$5.94M-$8.87M-$4.35M$14.42M-$5.68M-$7.18M-$29.67M-$32.61M
    Net income-$6.12M-$6.46M-$6.80M-$11.95M-$5.53M$4.17M-$9.58M$13.79M-$5.51M-$6.97M-$30.70M-$32.34M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $116.00K by $20.62M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$32.07M$35.20M$125.84M$182.24M$247.06M$271.16M$232.96M$190.82M$97.00M$63.83M
    Current assets$31.54M$31.69M$116.16M$168.91M$173.29M$195.06M$165.66M$168.14M$95.06M$61.45M
    Cash and equivalents$20.73M$31.61M$51.77M$63.74M$13.45M$31.68M$18.30M$15.08M$9.39M$12.09M
    Total liabilities$11.13M$40.83M$68.76M$23.46M$19.53M$22.16M$46.25M$57.19M$10.22M$13.10M
    Short-term debt$116.00KN/A$93.00K$2.00M$1.75M$1.60MN/AN/AN/AN/A
    Long-term debtN/A$30.26MN/AN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$20.95M-$91.13M$57.09M$158.78M$227.52M$249.00M$186.71M$133.63M$86.78M$50.73M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$23.53M$17.52M$25.82M$32.07M$39.02M$43.75M$38.95M$43.83M$51.33M$72.50M$90.10M$27.00M
    Total liabilities$8.08M$9.13M$11.31M$11.13M$11.15M$10.82M$47.02M$48.42M$50.62M$60.90M$60.30M$89.06M
    Cash and equivalents$22.27M$15.77M$19.85M$20.73M$21.42M$20.65M$34.22M$37.90M$37.06M$49.24M$47.00M$22.92M
    Shareholder equity$15.46M$8.38M$14.51M$20.95M$27.87M$32.93M-$8.07M-$4.59M$707.00K$11.60M$29.80M-$62.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$23.50M-$18.30M-$92.08M-$78.73M-$60.09M-$5.49M-$109.22M-$22.30M-$54.83M-$47.38M
    Capital expenditures$0$1.05M$2.38M$43.00K$39.00K$349.00K$18.00K$73.00K$58.00K$717.00K
    Free cash flow-$23.50M-$19.35M-$94.45M-$78.77M-$60.13M-$5.84M-$109.24M-$22.37M-$54.88M-$48.10M
    Dividends paid$2.82M$1.30MN/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$10.08M$0$43.46M$128.71M-$4.75M-$20.27M-$30.52M-$82.82M-$36.50M$45.02M
    Financing cash flow$22.70M$27.00M$38.15M$311.00K$46.61M$39.14M$142.60M$110.81M$87.92M$123.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.38M-$9.23M-$5.86M-$5.68M-$4.26M-$5.87M-$7.69M-$4.83M-$6.66M$23.64M-$30.45M-$17.37M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$210.00K$836.00K$2.05M
    Free cash flowN/AN/A-$5.86M-$5.68M-$4.26M-$5.87M-$7.69M-$4.83M-$6.66M$23.43M-$31.29M-$19.42M
    Last 12 quarters

    Frequently Asked Questions About TVRD

    What is Tvardi Therapeutics' annual revenue?

    Tvardi Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Tvardi Therapeutics profitable?

    No. Tvardi Therapeutics reported net income of -$18.21M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TVRD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.50M minus capital expenditures of $0 produced free cash flow of -$23.50M.

    How much debt does Tvardi Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $116.00K and cash and equivalents of $20.73M.